查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1358086

全身麻醉剂市场：依药物分子、给药途径、最终使用者、地区

General Anesthesia Drugs Market, By Drug molecule, By Route of Administration, By End User, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 200 Pages | 商品交期: 2-3个工作天内

价格
简介目录

预计 2023 年全球全身麻醉剂市场规模将达到 49.5 亿美元，预计在预测期内（2023-2030 年）年复合成长率为 4.1%。

报告范围 报告详情
基准年 2022年 2023年市场规模 49.5亿美元
实绩资料 2018-2021 预测期 2023-2030
预测期年复合成长率 4.10% 2030年市场规模预测 65.7亿美元
全身麻醉剂的全球市场占有率(%)（依给药途径），2023 年
全身麻醉药品市场-IMG1

全麻醉剂会抑制大脑层面的感觉、运动、交感神经传递，导致患者失去知觉、感觉缺失、无法感受疼痛刺激，同时控制不自主反射，这是一种表现出来的现象。全身麻醉剂有两种给药途径：静脉麻醉剂（含丙泊酚、依托咪酯、美索比妥、硫喷妥钠、咪达唑仑和氯胺酮等药物分子）和吸入麻醉剂（含地氟烷、异氟烷和七氟烷等药物分子）。主要企业主要致力于修改现有药物动力学或药物类别的化学结构，以改善其药物动力学、药效学和副作用特性。我们也正在开发可能使用TCI（标靶输注）的药物。现有麻醉剂的新应用也在探索中。因此，在市场上引入副作用较少的药物和有针对性的控制输注预计将在预测期内推动全球全身麻醉剂市场的成长。

市场动态

药理学产业的主要参与者致力于改进现有药物，以开发副作用较少的药物。例如，2022年7月，全球製药公司Cosmo Pharmaceuticals宣布，用于静脉麻醉的新型苯二氮平类药物BYFAVO已获得美国食品药物管理局（FDA）核准用于手术镇静和全身核准。药物（雷马唑仑）。瑞马唑仑为超短效药物，与目前使用的其他苯二氮平类全身麻醉剂相比，镇静持续时间短，恢復时间短，长期给药后蓄积少，副作用少。因此，将此类副作用较少的药物引入市场有望为製药商提供开发副作用较少的新药物的机会。

本研究的主要特点

  • 本报告详细分析了全球全身麻醉剂市场，并提供了以2022年为基准年的预测期（2023-2030）的市场规模和复合年度（年复合成长率）。它还强调了各个细分市场的潜在收益成长机会，并为该市场说明了一系列有吸引力的投资提案。
  • 它还提供了有关市场促进因素、抑制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要考察。
  • 它根据公司亮点、产品系列、主要亮点、财务实绩和策略等参数，介绍了全球全身麻醉剂市场的主要企业。
  • 该报告的见解使行销人员和公司负责人能够就未来的产品发布、类型经营团队、市场扩张和行销策略做出资讯的决策。
  • 本研究报告针对该产业的各个相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
  • 透过用于分析全球全身麻醉剂市场的各种策略矩阵，将有助于相关人员做出决策。

目录

第1章调查目的和假设

  • 这项研究的目的
  • 假设
  • 简称

第2章市场展望

  • 报告说明
    • 市场定义和范围
  • 执行摘要

第3章市场动态、法规及趋势分析

  • 市场动态
    • 促进因素
    • 抑制因素
    • 市场机会
  • 影响分析
  • 最近的发展
  • 管道分析
  • 配销通路分析
  • 流行病学
  • 合併、收购和合作
  • 法规场景
  • 主要进展
  • PEST分析

第4章全球全身麻醉剂市场 - COVID-19 的影响分析

  • 经济影响
  • 新型冠状病毒感染疾病（COVID-19）的流行病学
  • 对需求和供给的影响

第5章全球全身麻醉剂市场：依药物分子划分，2018-2030

  • 地氟烷
  • 异氟烷
  • 七氟醚
  • 异丙酚
  • 依托咪酯
  • 美索比妥
  • 硫喷妥钠
  • 咪达唑仑
  • 氯胺酮

第6章全球全身麻醉剂市场：依给药途径分类，2018-2030

  • 静脉麻醉
  • 吸入麻醉

第7章全球全身麻醉剂市场：依最终使用者划分，2018-2030 年

  • 医院
  • 专科诊所
  • 门诊手术中心

第8章全球全身麻醉剂市场：依地区划分，2018-2030

  • 北美洲
  • 美国
  • 加拿大
  • 欧洲
  • 英国
  • 德国
  • 义大利
  • 法国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
  • 亚太地区
  • 中国
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韩国
  • 其他亚太地区
  • 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲
  • 中东
  • GCC
  • 以色列
  • 其他中东地区
  • 非洲
  • 北非
  • 中部非洲
  • 南非

第9章竞争形势

  • 公司简介
    • Baxter Healthcare
    • Reddy's Laboratories
    • Novartis International AG
    • Hospira
    • Maruishi
    • Hengrui
    • Lunan
    • Fresenius Kabi
    • Pfizer Inc.
    • Hikma Pharmaceuticals
    • Sagent Pharmaceuticals
    • Teva Pharmaceuticals
    • Par Pharmaceutical
    • Viatris Inc.
    • AbbVie
    • Piramal Critical Care
    • Aspen Global Incorporated
    • B. Braun SE
    • Abbott
    • Cosmo pharmaceuticals

第10章章

  • 参考
  • 调查方法
简介目录
Product Code: CMI524

The global general anesthesia drug market is estimated to be valued at US$ 4.95 Billion in 2023 and is expected to exhibit a CAGR of 4.1% during the forecast period (2023-2030).

Report Coverage Report Details
Base Year: 2022 Market Size in 2023: US$ 4.95 Bn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 4.10% 2030 Value Projection: US$ 6.57 Bn
Global Anesthesia Drug Market Share (%), By Route of Administration, 2023
General Anesthesia Drugs Market - IMG1

General anesthesia drugs are meant to manifest unconscious patient by the inhibition of sensory, motor, and sympathetic nerve transmission at the level of the brain that results in unconsciousness and lack of sensation and incapable to feel painful stimuli while controlling involuntary reflexes. General anesthesia drugs are administrated by two routes either by intravenous anesthetics that includes drug molecules like propofol, etomidate, methohexital, thiopentone, midazolam and ketamine and other is inhalation anesthetics that includes drug molecules like desflurane, isoflurane, and sevoflurane. The key players are primarily focusing on modifying the chemical structures of existing drugs or drug classes with a direction to improve their pharmacokinetic, pharmacodynamics, and side effect properties. Furthermore, they are developing drugs that have possibilities of using Target Controlled Infusion (TCI). The new applications of pre-existing anesthetic drugs are being explored. Thus, the introduction of such drugs with lesser side effects and target controlled infusion in the market are expected to drive the growth of the global general anesthesia drugs market over the forecast period.

Market Dynamics

The key players in the pharmacology industry are focusing on the development of drugs with lesser side effects by the modification of preexisting drugs. For instance, in July 2022, Cosmo pharmaceuticals, a global pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved BYFAVO (Remimazolam), a novel benzodiazepine for intravenous anesthetics approved for use as procedural sedation and general anesthesia. It has an ultra-short duration of action and it uses target controlled infusion with short and expected duration of sedative action, short recovery time, rare accumulation after long-term infusion, and lesser side effects as compared to those of other currently used Benzodiazepines molecule of general anesthesia drugs. Thus, the introduction of such drugs with lesser side effects in the market is expected offer opportunities for drug manufacturers to develop more novel drugs with lesser side effects.

Key features of the study:

  • This report provides an in-depth analysis of the global general anesthetic drug market and provides market size (US$ Billion) and Compound Annual Growth Rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year. It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global general anesthetic drug market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • The key companies covered as a part of this study include Baxter Healthcare, Dr. Reddy's Laboratories, Fresenius Kabi, Pfizer Inc., Hikma Pharmaceuticals, Sagent Pharmaceuticals, Teva Pharmaceuticals, Par Pharmaceutical, Viatris Inc., AbbVie, Piramal Critical Care, Aspen Global Incorporated, B. Braun SE, Abbott, COSMO PHARMACEUTICALS, Hospira Inc., Maruishi, Hengrui, and Lunan
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global general anesthetic drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global general anesthetic drug market.

Detailed Segmentation:

  • Global General Anesthesia Drugs Market, By Drug molecule:
    • Desflurane
    • Isoflurane
    • Sevoflurane
    • Propofol
    • Etomidate
    • Methohexital
    • Thiopentone
    • Midazolam
    • Ketamine
  • Global General Anesthesia Drugs Market, By Route of Administration:
    • Intravenous Anesthesia
    • Inhalation Anesthesia
  • Global General Anesthesia Drugs Market, By End User:
    • Hospital
    • Specialty Clinics
    • Ambulatory Surgical Centers
  • Global General Anesthesia Drugs Market, By Region:
    • North America
    • Latin America
    • Europe
    • Asia Pacific
    • Middle East
    • Africa
  • Company Profiles
    • Baxter Healthcare
    • Dr. Reddy's Laboratories
    • Novartis International AG
    • Hospira
    • Maruishi
    • Hengrui
    • Lunan
    • Fresenius Kabi
    • Pfizer Inc.
    • Hikma Pharmaceuticals
    • Sagent Pharmaceuticals
    • Teva Pharmaceuticals
    • Par Pharmaceutical
    • Viatris Inc.
    • AbbVie
    • Piramal Critical Care
    • Aspen Global Incorporated
    • B. Braun SE
    • Abbott
    • Cosmo pharmaceuticals

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Molecule
    • Market Snippet, By Route of Administration
    • Market Snippet, By End User
    • Market Snippet, By Region
    • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Recent Development
  • Pipeline Analysis
  • Distribution Channel Analysis
  • Epidemiology
  • Merger, Acquisition, and Collaborations
  • Regulatory Scenario
  • Key Developments
  • PEST Analysis

4. Global General Anesthesia Drug Market - COVID-19 Impact Analysis

  • Economic Impact
  • COVID-19 Epidemiology
  • Impact on Supply and Demand

5. Global General Anesthesia Drug Market , By Drug Molecule, 2018 - 2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Desflurane
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends
  • Isoflurane
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends
  • Propofol
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends
  • Etomidate
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends
  • Etomidate
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends
  • Thiopentone
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends
  • Midazolam
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends
  • Ketamine
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends

6. Global General Anesthesia Drug Market , By Route of Administration, 2018 - 2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Intravenous Anesthesia
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends
  • Inhalation Anesthesia
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends

7. Global General Anesthesia Drug Market , By End User, 2018 - 2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Hospital
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
  • Specialty Clinics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
  • Ambulatory Surgical Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)

8. Global General Anesthesia Drug Market , By Region, 2018 - 2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • North America
    • Introduction
    • Market Size and Forecast,Y-o-Y Growth and By Drug Molecule, 2018 -2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 -2030, (US$ Bn)
    • Market Size and Forecast,Y-o-Y Growth and By End User, 2018 - 2030, (US$ Bn)
    • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Bn)
  • U.S.
  • Canada
  • Europe
    • Introduction
    • Market Size and Forecast,Y-o-Y Growth and By Drug Molecule, 2018 -2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 - 2030, (US$ Bn)
    • Market Size and Forecast,Y-o-Y Growth and By End User, 2018 - 2030, (US$ Bn)
    • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Bn)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast,Y-o-Y Growth and By Drug Molecule, 2018 -2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 - 2030, (US$ Bn)
    • Market Size and Forecast,Y-o-Y Growth and By End User, 2018 - 2030, (US$ Bn)
    • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Bn)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
    • Introduction
    • Market Size and Forecast,Y-o-Y Growth and By Drug Molecule, 2018 -2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 - 2030, (US$ Bn)
    • Market Size and Forecast,Y-o-Y Growth and By End User, 2018 - 2030, (US$ Bn)
    • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Bn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Middle East
    • Introduction
    • Market Size and Forecast,Y-o-Y Growth and By Drug Molecule, 2018 -2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 - 2030, (US$ Bn)
    • Market Size and Forecast,Y-o-Y Growth and By End User, 2018 - 2030, (US$ Bn)
    • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Bn)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast,Y-o-Y Growth and By Drug Molecule, 2018 -2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 - 2030, (US$ Bn)
    • Market Size and Forecast,Y-o-Y Growth and By End User, 2018 - 2030, (US$ Bn)
    • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Bn)
  • North Africa
  • Central Africa
  • South Africa

9. Competitive Landscape

  • Company Profiles
    • Baxter Healthcare
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Strategies
    • Reddy's Laboratories
    • Novartis International AG
    • Hospira
    • Maruishi
    • Hengrui
    • Lunan
    • Fresenius Kabi
    • Pfizer Inc.
    • Hikma Pharmaceuticals
    • Sagent Pharmaceuticals
    • Teva Pharmaceuticals
    • Par Pharmaceutical
    • Viatris Inc.
    • AbbVie
    • Piramal Critical Care
    • Aspen Global Incorporated
    • B. Braun SE
    • Abbott
    • Cosmo pharmaceuticals

10. Section

  • References
  • Research Methodology
  • About us and Sales Contact